Kamagra repose sur le sildénafil comme principe actif, avec un mode d’action identique à celui du Viagra. La forme galénique en gel oral permet une absorption plus rapide et une concentration plasmatique maximale plus précoce que les comprimés. Le mécanisme implique l’inhibition compétitive de la PDE5, entraînant une relaxation musculaire lisse locale et une vasodilatation ciblée. La demi-vie courte, environ 4 heures, limite la durée d’action. L’élimination se fait après métabolisme hépatique, impliquant majoritairement le CYP3A4. L’incidence d’effets indésirables comprend céphalées, rougeurs et congestion nasale, de façon transitoire. Dans les comparatifs pharmacologiques, acheter kamagra sans ordonnance est associé aux présentations galéniques alternatives disponibles.

Microsoft word - program

Symposium for Rheumatologists, Immunologists and
Pediatricians (in French):
Maladies fébriles récurrentes et syndromes auto-inflammatoires : Diagnostic et traitement de l’enfant à l’adulte Young Investigators Meeting
Opening Ceremony:
Jurg Tschopp Memorial Lecture:
What’s new in auto-inflammation since 2010? : Michael McDermott, Tribute to Jurg Tschopp: Fabio Martinon, Epalinges, Switzerland Welcome Reception
Joost Frenkel: News on the treatment of HIDS François Spertini: Adverse events and allergic responses to Session 1: CAPS and inflammasome
Update on IL-1 dysregulation, Charles Dinarello, Denver, USA NLRs, Basic mechanism of action and relevance in diseases: Jenny Mutation negative CAPS: Joost Frenkel, Utrecht, Netherlands Coffee break
Session 2: FMF
SAA, amyloidosis and cell damage: Bouke Hazenberg, Groningen, FMF heterozygotes: Véronique Hentgen, Versailles, France Treatment of FMF in 2013: Seza Ozen, Ankara, Turkey Session 3: Granulomatous diseases
Physiopathology of granuloma: Frédéric Altare, Nantes, France Immunodeficiency and Granulomatosis: Alexandre Belot, Lyon, Auto-inflammatory granulomatous diseases: Carine Wouters, Workshops
1. Genetic: Taxonomy of hereditary auto-inflammatory diseases: Eldad Ben Chetrit, Jerusalem, Israel 2. Biomarkers (S100A proteins, cytokines, CRP-SAA) Dirk Holzinger, Münster, Germany 3. Patient oriented research techniques in the auto-inflammatory Coffee break
Session 4: Monogenic autoinflammatory diseases
ER and stress: Fabio Martinon, Epalinges, Switzerland Immunoproteosome: Ivona Aksentijevitch, Bethesda, USA New monogenic auto-inflammatory periodic syndromes: Marco PRO-CON: Controversies on the mode of inheritance of AIDs
Isabelle Touitou, Montpellier, France and Michael Morris, Geneva, Jasmine Kummerle-Deschner: Practical diagnostic aspects of CAPS Anna Simon: Triggering causes for AID and attack prevention Seza Ozen: Practical aspects of FMF treatment Hans Acha-Orbea: Inflammasome activation in different diseases Session 5: Non-monogenic AIDs
Genome wide association studies in polygenic AIDs: Dan Kastner, Chronic recurrent multifocal osteomyelitis: Hermann Girschick, PFAPA Syndrome: Michaël Hofer, Lausanne, Switzerland Coffee break
Session 6+7: Abstract presentations
Coffee break
Session 8: Systemic-onset JIA and AOSD
Update on the pathophysiology of So-JIA and AOSD: Virginia Update on the treatment of So-JIA in 2013: Rolando Cimaz, PRO-CON: Prednisone versus Biotherapy in early treatment of So-
Alberto Martini, Genoa, Italy / Nico Wullfraat, Utrecht, Netherland Jasmine Kummerle-Deschner: Long-term CAPS treatment by anti- Anna Simon: How to do research on diseases with intermittent Rolando Cimaz: Practical aspects of biotherapies in SOJIA Mike Morris: Guidelines for genetic diagnosis of hereditary fevers Alexander So: Microcristals and inflammation Session 9: Behçet
Pathogenesis of Behcet's disease: HLA and beyond: Ahmed Gül, Treatment of Behçet’s uveitis: Yan Guex-Crosier, Lausanne, Behçet registry, PED-BD: Isabelle Kone-Paut, Kremlin-Bicêtre, Coffee break
Session 10+11: Abstract presentations
Session 12: New developments in auto-inflammation: new
diseases and therapeutic targets
Diabetes and auto-inflammation, Mark Donath, Zurich Switzerland Auto-inflammation in the skin, psoriasis: Michel Gilliet, Lausanne, New targets for the treatment of auto-inflammatory diseases: Coffee break
Session 13: Late breaking abstracts
Congress dinner
Session 14: New developments in auto-inflammation: from
regulation to biotherapies
Regulatory cytokines and cells dampening (auto-) inflammation: Side effects of biotherapies, novel aspects: David Isenberg, London, Coffee break
Session 15: Difficult case presentations

Source: http://www.sobifrance.fr/uploads/media/Programme_Congr%C3%A8s_ISSAID_-_Mai_2013.pdf